Surgical Science Sweden AB (publ)

company Surgical Science have released its report for the third quarter in 2022. I therefore have its CEO Gisli Hennemark with me in the studio. Welcome, Gisli. Thank you, Mattias. So, you know, we like to start with the numbers, so I'll jump right into it. So for the third quarter in 2022, you reported net sales amounted to 205.1 million Swedish kronas compared to 95.3 in the corresponding quarter 2021. And the operating profit came in on 42.7 million compared to 7.6 last year. What is your comment to these numbers?

Well, there are great numbers. That's my first comment. And to go beyond 200 million Swedish crowns in a quarter is a record for us. So we're very happy with the Q3 quarter. Especially when you consider that the comparables are more challenging now, because we did have a great quarter last year. And actually, if you read the report a bit more detailed from last year, a significant contributor on the educational product side was Russia. So to start the quarter, with sort of not having that revenue and then still educational products coming in at 138 million Swedish crowns in a quarter is fantastic. I mean, educational products have really been, you know, powertrain for us. This is where we sell our own simulators, our own branded simulators to the university hospitals. And then industry OEM is doing good. Solid license revenue, 40 million Swedish crowns. This is when we license our technology to circle robotic companies. But also the other revenue streams there like simulator sales where we do both hardware and software combined to our med device customers grew. License revenue went down a bit from Q2. But there is some lumpiness, especially from the new circle robotic entrants that have a buying pattern where they buy a little bit more in bundles. And also when they come out with new products, they sometimes do series of their products to to get feedback and then adjust. So there is a little bit of variability. But overall, fantastic sales and the profit level is good. I mean, if we look at adjusted EBIT, which is what we like to measure, because then we add back amortizations on acquisitions, you know, almost one dollar out of four is profit. So very good quarter for us.

How is your sales distributed on your various markets?